HOME >> MEDICINE >> NEWS
Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial

Copenhagen, Denmark: Eagerly awaited results from the world's first head to head trial between the anti-cancer drugs docetaxel (Taxotere) and paclitaxel (Taxol)[1] have shown that there was a better overall response rate and longer overall survival among breast cancer patients given docetaxel although docetaxel was associated with more severe side effects.

The new results were presented for the first time today (Wednesday 24 September) at ECCO 12 The European Cancer Conference taking place in Copenhagen.

Four hundred and forty nine women with advanced incurable breast cancer who had received previous treatment with an anthracycline-based chemotherapy were randomised into the Phase III trial from multiple centres across the USA between 1994 and 20012. Half were treated with paclitaxel and half were treated with docetaxel.

The trial's principal investigator, Professor Peter Ravdin, associate professor in the Department of Medicine at the University of Texas Health Science Center in San Antonio, told a news briefing that the women treated with docetaxel survived for a median 15.4 months compared with a median 12.7 months for the women who received paclitaxel.

There was an overall response rate of nearly a third among the docetaxel patients compared with a quarter for the paclitaxel patients. The median time before the breast cancer progressed (TTP) was 5.7 months for the docetaxel patients and 3.6 months for the paclitaxel patients. The results for overall survival and for TTP were statistically significantly superior for docetaxel and the overall response rate in favour of docetaxel approached statistical significance.

However, the women who received docetaxel did experience more severe side effects (grade 3/4 toxicities) with higher incidences of neutropenia (reduction in infection-fighting white blood cells), asthenia (loss of strength), infection, oedema (abnormal accumulation of fluid), mouth ulcers and neuromotor and n
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
45-3252-4163
Federation of European Cancer Societies
24-Sep-2003


Page: 1 2

Related medicine news :

1. Good intentions versus bad habits: Why the old ways win out
2. Normal aging versus Alzheimers disease and the potential for prevention
3. Regulatory T cells keep graft-versus-host disease in check
4. Study evaluates Abacavir, Lamivudine and Efavirenz versus Zidovudine, Lamivudine and Efavirenz
5. U-M study finds new target in war against graft-versus-host disease
6. Weekly Taxol (paclitaxel) plus Paraplatin (carboplatin) is safe and effective in patients with advanced lung cancer
7. International breast cancer prevention study launches in the United States and Canada
8. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
9. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
Breaking Medicine Technology:
Cached News: